Welcome to the 8th EAS Paediatric Familial Hypercholesterolemia Symposium
Saturday, 3 May 2025, Glasgow, UK
This event will take place in Crowne Plaza Glasgow (Congress Rd, Glasgow G3 8QT, UK)
*No virtual/ online participation participation
Registration for free – REGISTER HERE
Registration will close on 25 April, 2025
Programme
Organised by:
Uma Ramaswami, Alison Cozens, Jeanine Roeters van Lennep, Urh Grošelj, Mafalda Bourbon, Kirsten Holven, Michal Vrablik, and Steve Humphries
| 09.00-09.05 | Welcome – Uma Ramaswami & Alison Cozens & Jules Payne (HEART UK) |
| 09.05-10.25 | Clinical utility of knowing the underlying genetic cause of the FH phenotype in children Chairs: Steve Humphries (UK) and Mafalda Bourbon (Portugal) |
| 09.05-09.20 | Development and implementation of a LDL-C Polygenic Risk Score (PRS) – Mafalda Bourbon (Portugal) |
| 09.20-09.35 | What do Health Care Professionals and Patients think of the usefulness of the LDL-C SNP Score: the UK experience – Lisa Gritzmacher (UK) |
| 09.35-09.50 | LPA and other new genes for the FH Phenotype – Marta Futema (UK) |
| 09.50-10.05 | Does knowing the genetic cause of FH help decide the best lipid-lowering treatment? – Gilles Lambert (France) |
| 10.05-10.25 | Panel Discussion |
| 10.25-11.00 | Coffee break |
| 11.00-12.50 | Do we need a new clinical FH diagnostic score for children? Chairs: Jeanine Roeters van Lennep (The Netherlands) and Uma Ramaswami (UK) |
| 11.00-11.10 | Process and consensus committee for EAS Guidelines – Jeanine Roeters van Lennep (Netherlands) |
| 11.10-11.30 | Update of the EAS Paediatric FH Guidelines: new recommendations for 2025 – Albert Wiegman (Netherlands) |
| 11.30-11.50 | Italian algorithm for identifying children with FH – Ornella Guardamagna (Italy) |
| 11.50-12.10 | Can we develop a modified DLCN score to be used in children – Jan Kafol (Slovenia) |
| 12.10-12.30 | How will the new Guidelines influence clinical practice and help in deciding when to initiate Lipid-lowering therapy – Uma Ramaswami (UK) |
| 12.30 -12.50 | Round table discussion with all Topic 3 speakers plus Patient Representative plus Alison Cozens plus Jules Payne (HEARTUK) and Magdalena Daccord (FH Europe Foundation) |
| 12.50-13.50 | Lunch break |
| 13.50-15.00 | Treating children with HoFH : novel agents and PCSK9i/ANGPTL3i Chairs: Michal Vrablik (Czech Republic), Alison Cozens (UK) & Urh Grošelj (Slovenia) |
| 13.50-14.05 | Inhibiting PCSK9 and ANGPTL3– Derick Raal (South Africa) |
| 14.05-14.20 | Patient experience of monoclonal antibody treatment – Adam Barratt |
| 14.20-14.35 | ANGPTL3 gene editing to treat HoFH – Amit Kehera (Verve, USA) |
| 14.35-14.50 | Use of Bempadoic Acid to treat chldren with HeFH – Ioanna Gouni-Berthold (Germany) |
| 14.50-15.00 | Panel discussion |
| 15.00-15.10 | Voting for next year’s topics and Wrap up – Steve Humphries (UK) |
| 15.10-16.30 | Networking drinks |
*The symposium is free of charge for all delegates. Please note that a no-show fee of €100 will be charged if you cancel your participation later than Friday 18 April or do not show up at the symposium.
Thank you to our sponsors
